Treating preterm infants with an erythropoiesis-stimulating agent such as darbepoetin alfa can help decrease the use of red blood cell transfusions, according to a study in the journal Pediatrics. Infants given the drugs in a trial at high-altitude hospitals were given fewer transfusions. Fifty-nine percent of infants administered darbepoetin alfa and 52% of infants given erythropoietin did not receive transfusions, compared with 38% for the placebo group.
Premature newborns' need for transfusions declines with ESA use
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan